PTC Therapeutics, Inc. completed a private offering of $550,000,000 in 0.0% Convertible Senior Notes due 2031. The company plans to use approximately $328.8 million of the net proceeds to repurchase $222.0 million of its existing 1.50% Convertible Senior Notes due 2026. PTC Therapeutics, Inc. is a biotechnology company that develops and commercializes therapeutic solutions for life-threatening diseases.
